A Cancer Research UK Phase I Trial of Adoptive Transfer of Autologous Tumor Antigen-Specific T Cells With Preconditioning Chemotherapy and Intravenous IL2 in Patients With Advanced CEA Positive Tumors.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin; Autologous MFE23-expressing T-lymphocytes; Cyclophosphamide; Fludarabine
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Acronyms MFEz
Most Recent Events
- 31 May 2012 New source identified and integrated (United Kingdom Clinical Research Network; 6499).
- 28 Feb 2012 Biomarkers information updated
- 27 Feb 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.